Kyung Dong Pharmaceutical Co., Ltd.

KOSDAQ:A011040 Voorraadrapport

Marktkapitalisatie: ₩170.5b

Kyung Dong Pharmaceutical Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Kyung Dong Pharmaceutical's earnings have been declining at an average annual rate of -39.4%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 0.4% per year.

Belangrijke informatie

-39.4%

Groei van de winst

-41.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie11.3%
Inkomstengroei-0.4%
Rendement op eigen vermogen-7.4%
Nettomarge-9.1%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Mar 07
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Feb 18
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Feb 03
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Jan 19
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

Jan 04
Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

Dec 20
How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Dec 05
We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Opbrengsten en kosten

Hoe Kyung Dong Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

KOSDAQ:A011040 Opbrengsten, kosten en inkomsten (KRW Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24178,594-16,19191,94014,841
31 Mar 24170,232-18,92088,36514,704
31 Dec 23162,674-20,70886,47113,827
30 Sep 23165,7096,48081,02413,189
30 Jun 23174,1438,36676,38513,287
31 Mar 23173,1098,42274,42311,951
31 Dec 22182,71812,16170,60212,618
30 Sep 22181,7986,50671,89712,469
30 Jun 22183,6839,17971,61012,137
31 Mar 22185,79312,29170,19811,813
31 Dec 21177,61112,67268,44410,537
30 Sep 21175,89413,57768,55710,877
30 Jun 21172,33211,66968,38010,146
31 Mar 21171,85311,08767,6949,767
31 Dec 20173,82812,45966,54010,063
30 Sep 20175,09112,91666,1309,818
30 Jun 20174,26318,54966,5069,490
31 Mar 20176,34820,78866,5379,589
31 Dec 19176,50020,12667,7378,918
30 Sep 19175,9065,75166,8918,262
30 Jun 19177,8423,15565,9157,142
31 Mar 19175,6023,19365,3796,274
31 Dec 18179,3165,24264,5515,869
30 Sep 18180,11216,91264,7455,510
30 Jun 18181,52818,70065,1655,626
31 Mar 18181,86120,56264,5135,778
31 Dec 17177,77220,47764,2655,648
30 Sep 17173,02222,22262,8765,667
30 Jun 17166,64019,44461,8805,735
31 Mar 17162,70318,67061,7945,336
31 Dec 16158,59917,60961,2265,033
30 Sep 16155,70518,62960,4115,090
30 Jun 16153,07913,67363,4105,061
31 Mar 16150,79313,92860,4365,956
31 Dec 15151,89314,13260,5245,156
30 Sep 15153,19515,39555,7937,783
30 Jun 15151,28822,40450,0236,758
31 Mar 15153,28622,92450,1534,747
31 Dec 14153,26024,51848,2534,771
30 Sep 14151,58123,89148,5204,226
30 Jun 14148,23625,78747,8534,229
31 Mar 14140,86324,59146,6084,232
31 Dec 13133,07418,85244,5474,231

Kwaliteitswinsten: A011040 is currently unprofitable.

Groeiende winstmarge: A011040 is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: A011040 is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.

Versnelling van de groei: Unable to compare A011040's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: A011040 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).


Rendement op eigen vermogen

Hoge ROE: A011040 has a negative Return on Equity (-7.42%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden